文献速递肾血管病与高血压慢性肾脏病

促红细胞生成素及相关分子诱导高血压的机制与介质

Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本综述批判性评估促红细胞生成素(EPO)诱导高血压的机制,先考虑临床前数据后结合临床数据。动物研究显示慢性肾脏病在EPO诱导高血压发生中起主要作用,一氧化氮、内皮素、前列腺素类物质及交感肾上腺和肾素-血管紧张素通路调节异常是原因。人类研究表明EPO给药与血管组织对儿茶酚胺和血管紧张素II反应性增加相关,缺氧诱导的血管舒张可能受损。EPO诱导的高血压至少部分独立于血红蛋白升高。

要点

  • EPO治疗常见但常被忽视的不良反应是高血压,可能因降压药使用或干体重关注而漏报。
  • 动物研究显示慢性肾脏病在EPO诱导高血压发生中起主要作用。
  • EPO诱导高血压至少部分独立于血红蛋白升高,实验显示EPO结合蛋白可升高血红蛋白而不升血压。

核心结论

  • EPO诱导高血压由多种分子介导的血管张力失衡所致,净效应为血管收缩。
  • EPO诱导高血压至少部分独立于血红蛋白升高。
  • 缺氧诱导因子稳定剂是否改变高血压风险与EPO相比尚待观察。

研究设计与样本

  • 综述,批判性评估EPO诱导高血压的机制,先考虑临床前数据后结合可用临床数据。

主要发现

  • 动物研究显示慢性肾脏病在EPO诱导高血压发生中起主要作用。
  • 临床前研究显示一氧化氮、内皮素、前列腺素类物质及交感肾上腺和肾素-血管紧张素通路调节异常是EPO诱导高血压的原因。
  • 人类研究表明EPO给药与血管组织对儿茶酚胺和血管紧张素II反应性增加相关,缺氧诱导的血管舒张可能受损。
  • 很少证据支持EPO作为直接血管收缩剂或通过血黏度效应作为EPO诱导高血压的机制。
  • 实验显示EPO结合蛋白可升高血红蛋白而不升血压,铁缺乏时EPO治疗可能不升血红蛋白但仍升血压。

临床怎么用

  • 临床应关注EPO治疗相关高血压,可能需调整降压药或关注干体重。
  • EPO诱导高血压机制复杂,涉及多种通路,临床管理需综合考虑。

局限性

  • 实验数据在各研究间不一致,需要更好的机制设计,尤其在慢性肾脏病患者中,以剖析EPO诱导高血压的精确机制。
  • 动物研究提示缺氧诱导因子稳定剂可能通过促钙化和加重慢性间歇性缺氧诱导高血压,但尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertension is a common but frequently overlooked adverse effect of erythropoietin (EPO) therapy. Underreporting of hypertension with EPO is likely due to either more aggressively managing hypertension through the prescription of antihypertensive drugs or closer attention to dry weight. The purpose and focus of this review is to critically evaluate the mechanisms of EPO-induced hypertension. Preclinical data are considered first, followed by clinical data where available. Mediated by a variety of molecules, there is an imbalance in the vascular tone favoring net vasoconstriction that mediates EPO-induced hypertension. Animal studies show the primary importance of chronic kidney disease in the genesis of EPO-induced hypertension. Preclinical studies show deranged regulation of the nitric oxide, endothelins and porstanoids and the sympathoadrenal and renin-angiotensin pathways as causes of EPO-induced hypertension. Human studies suggest that EPO administration is also associated with increased responsiveness to catecholamines and angiotensin II on vascular tissue; in addition, hypoxia-induced vasodilation may be impaired in those with EPO-induced hypertension. There is little evidence for EPO as a direct vasoconstrictor or its effect on blood viscosity as a mechanism of EPO-induced hypertension. EPO-induced hypertension, at least in part, appears to be independent of an increase in hemoglobin, because experiments show that hemoglobin may be increased by EPO without an increase in blood pressure (BP) by simply treating the animals with EPO-binding protein and that treatment with EPO in the setting of iron deficiency may not increase hemoglobin but may still increase BP. However, experimental data are not consistent across studies and better mechanistic designs are needed, especially in patients with chronic kidney disease, to dissect the precise mechanism of EPO-induced hypertension. Animal studies suggest that hypoxia-inducible factor stablizers may induce hypertension by provoking calcification and augmenting chronic intermittent hypoxia as occurs in sleep apnea. Others show that there may be an antihypertensive effect via kidney repair. Whether these drugs will alter the risk of hypertension compared with EPO remains to be seen.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrol Dial Transplant. 2018. PMID: 29228345. doi:10.1093/ndt/gfx324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。